Sun Pharmaceutical Industries Limited (SUNPHARMA) Price & Analysis

Compare

4 Followers

SUNPHARMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹1,555.00 - ₹1,960.20

Previous CloseN/A

Volume1.30M

Average Volume (3M)91.40K

Market Cap

₹4.08T

Enterprise Value₹4.06T

Total Cash (Recent Filing)₹249.88B

Total Debt (Recent Filing)₹23.62B

Price to Earnings (P/E)37.4

Beta0.62

Next Earnings

Jul 31, 2025

EPS Estimate

12.52

Last Dividend Ex-Date

Jul 07, 2025

Dividend Yield0.65%

Share Statistics

EPS (TTM)10.65

Shares Outstanding2,399,276,400

10 Day Avg. Volume67,220

30 Day Avg. Volume91,396

Financial Highlights & Ratios

PEG Ratio-8.58

Price to Book (P/B)5.71

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,961.25

Price Target Upside14.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Sun Pharmaceutical Industries Limited News

PremiumCompany Announcements

Sun Pharma’s Tildrakizumab Study: A Promising Step in Genital Psoriasis Treatment

15d ago

PremiumCompany Announcements

Sun Pharma’s Promising Phase 3 Study on Tildrakizumab for Genital Psoriasis

17d ago

PremiumCompany Announcements

Sun Pharma’s Sonidegib Safety Study: Key Insights for Investors

23d ago

PremiumCompany Announcements

Sun Pharma’s Tildrakizumab Study: A Potential Game-Changer for Psoriatic Arthritis

23d ago

PremiumCompany Announcements

Sun Pharma’s Tildrakizumab Study: A Potential Game-Changer for Psoriatic Arthritis Treatment

23d ago

PremiumCompany Announcements

Philogen Withdraws Nidlegy™ Application, Plans Resubmission

25d ago

PremiumCompany Announcements

Sun Pharma Schedules Analyst and Investor Meeting

25d ago

PremiumCompany Announcements

Sun Pharma’s Sonidegib Safety Study: Key Insights for Investors

25d ago

See All IN:SUNPHARMA News

See All News >

Financials

Income Statement >

SUNPHARMA FAQ

What was Sun Pharmaceutical Industries Limited’s price range in the past 12 months?

Sun Pharmaceutical Industries Limited lowest stock price was ₹1555.00 and its highest was ₹1960.20 in the past 12 months.

What is Sun Pharmaceutical Industries Limited’s market cap?

Sun Pharmaceutical Industries Limited’s market cap is ₹4.08T.

When is Sun Pharmaceutical Industries Limited’s upcoming earnings report date?

Sun Pharmaceutical Industries Limited’s upcoming earnings report date is Jul 31, 2025 which is in 12 days.

How were Sun Pharmaceutical Industries Limited’s earnings last quarter?

Sun Pharmaceutical Industries Limited released its earnings results on May 22, 2025. The company reported ₹10.65 earnings per share for the quarter, missing the consensus estimate of ₹11.654 by -₹1.004.

Is Sun Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Sun Pharmaceutical Industries Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sun Pharmaceutical Industries Limited pay dividends?

Sun Pharmaceutical Industries Limited pays a Semiannually dividend of ₹16 which represents an annual dividend yield of 0.65%. See more information on Sun Pharmaceutical Industries Limited dividends here

What is Sun Pharmaceutical Industries Limited’s EPS estimate?

Sun Pharmaceutical Industries Limited’s EPS estimate is 12.52.

How many shares outstanding does Sun Pharmaceutical Industries Limited have?

Sun Pharmaceutical Industries Limited has 2,399,276,400 shares outstanding.

What happened to Sun Pharmaceutical Industries Limited’s price movement after its last earnings report?

Sun Pharmaceutical Industries Limited reported an EPS of ₹10.65 in its last earnings report, missing expectations of ₹11.654. Following the earnings report the stock price went down -0.67%.

Which hedge fund is a major shareholder of Sun Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in IN:SUNPHARMA

Company Description

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited (SUNPHARMA) is a leading global pharmaceutical company headquartered in India. The company specializes in the manufacturing and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Sun Pharma's product portfolio includes generics, branded generics, specialty pharmaceuticals, and over-the-counter (OTC) products, catering to various therapeutic segments such as cardiology, psychiatry, neurology, gastroenterology, and more. The company operates in multiple countries, selling its products in over 100 markets worldwide, making it one of the largest pharmaceutical companies in the world.

SUNPHARMA Stock 12 Month Forecast

Average Price Target

₹1,961.25

▲(14.03%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1441":"₹1,441","1826":"₹1,826","2211":"₹2,211","1633.5":"₹1,633.5","2018.5":"₹2,018.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.21K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1961.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.96K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1441,1633.5,1826,2018.5,2211],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1661.73,1703.9046153846155,1746.079230769231,1788.253846153846,1830.4284615384615,1872.603076923077,1914.7776923076924,1956.9523076923078,1999.126923076923,2041.3015384615385,2083.476153846154,2125.650769230769,2167.825384615385,{"y":2210,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1661.73,1684.77,1707.81,1730.85,1753.89,1776.93,1799.97,1823.01,1846.05,1869.09,1892.13,1915.17,1938.21,{"y":1961.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1661.73,1649.2892307692307,1636.8484615384616,1624.4076923076923,1611.9669230769232,1599.5261538461539,1587.0853846153846,1574.6446153846155,1562.2038461538461,1549.7630769230768,1537.3223076923077,1524.8815384615384,1512.4407692307693,{"y":1500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1442.08,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1499.11,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1700.08,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1799.95,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1901.65,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1901.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1791.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1872.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1726.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1588.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1691.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1824.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1661.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >